Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
出版年份 2021 全文链接
标题
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 3, Pages e001621
出版商
BMJ
发表日期
2021-03-31
DOI
10.1136/jitc-2020-001621
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
- (2020) Mariaelena Capone et al. Journal of Translational Medicine
- High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
- (2019) Viola Franke et al. INTERNATIONAL JOURNAL OF CANCER
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition
- (2019) Victoria A. Jennings et al. MOLECULAR THERAPY
- Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
- (2019) Praveen K. Bommareddy et al. OncoImmunology
- Correlates of response and outcomes with talimogene laherperpvec
- (2019) Alice Y. Zhou et al. JOURNAL OF SURGICAL ONCOLOGY
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size
- (2019) Sabran J. Masoud et al. ANNALS OF SURGICAL ONCOLOGY
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- (2019) David Liu et al. NATURE MEDICINE
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
- (2018) Kristina Buder-Bakhaya et al. Frontiers in Immunology
- Melanoma Immunotherapy: Next-Generation Biomarkers
- (2018) Sabrina A. Hogan et al. Frontiers in Oncology
- 60PResponse rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials
- (2018) H Gogas et al. ANNALS OF ONCOLOGY
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Current status and perspectives in immunotherapy for metastatic melanoma
- (2017) Riccardo Marconcini et al. Oncotarget
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- The immune system and cancer evasion strategies: therapeutic concepts
- (2016) S. Muenst et al. JOURNAL OF INTERNAL MEDICINE
- Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
- (2016) J. Galon et al. Journal of Translational Medicine
- Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
- (2016) Kevin Harrington et al. OncoTargets and Therapy
- Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
- (2016) Hasan Rehman et al. Journal for ImmunoTherapy of Cancer
- Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
- (2016) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
- (2015) Shin Foong Ngiow et al. CANCER RESEARCH
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- A new paradigm for tumor immune escape: β-catenin-driven immune exclusion
- (2015) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma
- (2012) G. Erdag et al. CANCER RESEARCH
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now